ALTEOGEN
Blood & Organ Banks · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
62 Yuseong-daero 1628beon-Gil Yuseong-gu...Phone Number
+82 423848780Website
www.alteogen.comRevenue
$5.7 MillionStock Symbol
196170Industry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
4
3
4
4
2
2
About ALTEOGEN
Alteogen lnc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP-fusion and NexMab platform technology, respectively. It is also developing Eylea biosimilar. The company was founded in 2008 and listed in KOSDAQ (196170.KQ).Explore more
ALTEOGEN Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ALTEOGEN your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once ALTEOGEN has new funding data
Check if ALTEOGEN has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at ALTEOGEN
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ALTEOGEN launches new products
ALTEOGEN, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on ALTEOGEN recently announced quarterly report
Click to see if ALTEOGEN had a recent Job posting/layoffs
Check out if ALTEOGEN is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined ALTEOGEN as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
ALTEOGEN is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ALTEOGEN is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ALTEOGEN.
ALTEOGEN Tech Stack
A closer look at the technologies used by ALTEOGEN
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Events
Event
ALTEOGEN News & Media
Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, regulatory and sales milestone payments Additional royalties to be paid based on net sales following commercialization DAEJEON, South Korea, Aug. 5, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platformAlteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy Key Points Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4 Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity atBiogen Secures Exclusive Rights To Develop Subcutaneous Biologics Using Alteogen's ...
Biogen Secures Exclusive Rights To Develop Subcutaneous Biologics Using Alteogen’s ALT B4 PlatformAlteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology. Under the terms of the agreement, Biogen will obtain exclusi
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ALTEOGEN
Sign Up For FreeTo access detailed company insights
Alteogen lnc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP-fusion and Ne... Read More
